Clinical Trials

NIH Releases Statement Regarding AstraZeneca Vaccine

The National Institute of Allergy and Infectious Diseases (NIAID) published a news release today regarding AstraZeneca’s COVID-19 vaccine clinical trial, after being notified by the Data and Safety Monitoring Board that outdated information “may have provided an incomplete view of the efficacy data” (1). Which information is outdated has not been specifically disclosed. This statement was released one day after the NIH published a media advisory that the investigational AstraZeneca vaccine prevents COVID-19. 

Read More »

Some Long-Haulers Find Relief After Getting the COVID-19 Vaccine

Long-haulers are sharing stories of symptom relief after receiving the COVID-19 vaccine. While anecdotal as of now, patients from across the country are reporting that their symptoms have improved or even resolved after getting their first dose of the COVID-19 vaccine. Survivor Corps, one of the largest patient communities advocating for COVID-19 long haulers, recently released a poll on Facebook asking members how they felt post-vaccination. As of March 18, 2021, 40% of participants said that their long-COVID symptoms improved after being vaccinated. 

Read More »

The Johnson & Johnson COVID Vaccine + Autoimmune Disease

In early February 2021, Janssen Pharmaceutical Companies of Johnson & Johnson requested emergency authorization by the FDA to distribute their COVID-19 vaccine. Come the end of the month, the FDA will be reviewing their request; if approved, the Janssen COVID-19 vaccine could be rolled out across the U.S. as early as the end of March. 

Read More »

Clinical Trial Tests New Antibody Cocktail in Patients with COVID-19

On February 8, the NIH released a news statement announcing the implementation of a Phase 3 clinical trial for a new combination of antibodies as a therapy treatment for COVID-19. “Antibodies are infection-fighting proteins naturally made by the immune system… [they] prevent viruses from infecting cells, usually by binding to the surface of the virus”.

Read More »